Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

In-Vitro Toxicology Testing Market worth $17,227 Million by 2018 - New Report by MarketsandMarkets
  • USA - English


News provided by

MarketsandMarkets

Jun 03, 2014, 13:45 ET

Share this article

Share toX

Share this article

Share toX

MarketsandMarkets
MarketsandMarkets

(PRWEB) June 03, 2014 -- The “In-Vitro Toxicology/ Toxicity Testing Market by Industry (Diagnostic, Pharmaceutical, Cosmetics, Chemical), Technology (Cell Culture, HTS, Omics), Applications (Systemic, Dermal, Ocular),Method (Cellular Assay, Ex vivo, In Silico) - Global Forecast to 2018”.

Browse 67 market data tables, 25 figures spread through 246 pages and in-depth TOC.
http://www.marketsandmarkets.com/Market-Reports/in-vitro-toxicology-testing-market-209577065.html

Early buyers will receive 10% customization on this report.

Key Players - Charles River Laboratories (U.S.), Covance (U.S.), Cyprotex (U.K.), Eurofins Scientific, Inc (U.S.), GE Healthcare (U.K.), Life Technologies Corporation (Thermo Fisher Scientific) (U.S.), and Quest Diagnostics (U.S.)

Post this

The global market will reach $17,227 million by 2018 growing at a double-digit CAGR during the forecast period (2013–2018).

Inquire before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=209577065

The advances in the in vitro toxicology testing have presented a wide range of new technologies that help in investigating the adverse effects of environmental agents in a more mechanistic, less expensive, and time saving manner. The cell culture technology is the largest and will be the fastest growing market in the coming five years. In vitro toxicology cellular assays are of utmost interest for the initial toxicity screening of compounds in the process of drug development within the pharmaceutical industry. The 3D models are also gaining importance in in-vitro technology as they show major phenotype differences, greater stability, and longer life. These 3D models help to replicate the effect of drugs on human body to a great extent; hence, they are used for reducing the drug attrition rate.

Request for Customization @ http://www.marketsandmarkets.com/requestCustomization.asp?id=209577065

The In depth research in the in vitro toxicology testing market has brought to light that agreements, partnerships and collaboration is the key strategy followed by major players to enhance their existing portfolio. It accounted for 28% share of the total number of strategies. Major players such as Charles River Laboratories Inc. (U.S.), Covance, Inc. (U.S.), Alere, Inc. (U.S.), Agilent Technologies (U.S.), G.E. Healthcare (U.K.) and Cyprotex (U.K.) followed this strategy between 2011 and 2014. In November 2013, GE Healthcare entered into an agreement with France-based Cellectis Group; the same time Covance, Inc. reported its strategic collaboration with NeoGenomics, Inc. in U.S. and Pathoquest in France. The agreements/partnerships deals together have widened the companies’ offerings across geographies and added to their existing portfolio of products and services. These extended range of products and services are offered together by combining considerable medical leadership to encourage innovations that improve patient outcomes. Majority of the companies are relishing the chunk of revenues generated from the developed markets but have also tapped the enormous potential of the emerging markets.

Geographic analysis reveals that Europe commanded the largest share of the global in vitro toxicity testing market in 2013. This was credited to the support provided by the European government for anti-animal testing laws. The directives set by the government has further put ban on the production and sale of all animal tested cosmetics across the continent.

Globally, the market will be driven by increasing acceptance of in vitro toxicity testing methods by regulatory authorities as alternatives to in vivo testing. This has been primarily driven by demand for toxicological information on chemicals that are both existing and newly introduced into the market. The new advances in the in vitro toxicology testing have presented a wide range of new technologies that help in investigating the adverse effects of environmental agents in a more mechanistic, less expensive, and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in-vitro methods for toxicology testing. The emerging countries in Asia, such as China and India, will witness high growth on account of low cost offered by these countries as well as the economic stability observed within these countries.

The market is a highly fragmented one. The dominant players in this market are Agilent Technologies (U.S.), Alere, Inc. (U.S.), Bio-Rad (U.S.), BioReliance (Sigma Aldrich) (U.S.), Catalent Pharma Solutions (U.S.), Charles River Laboratories (U.S.), Covance (U.S.), Cyprotex (U.K.), Eurofins Scientific, Inc. (U.S.), GE Healthcare (U.K.), Life Technologies Corporation (Thermo Fisher Scientific) (U.S.), and Quest Diagnostics (U.S.).

Browse Related Reports:
Point-Of-Care Diagnostics / Testing Market by Products (Glucose Monitoring & Infectious Diseases Testing Kits, Cardiac & Tumor Markers), by End Users (Self & Professional Monitoring), Over the Counter & Prescription Based - Global Forecast to 2018
http://www.marketsandmarkets.com/Market-Reports/point-of-care-diagnostic-market-106829185.html

In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017
http://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html

About MarketsandMarkets
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales(at)marketsandmarkets(dot)com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

Mr. Rohan, MarketsandMarkets, http://www.marketsandmarkets.com/, +91 9881155004, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.